Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02580370 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines
A Phase 3 study, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
NCT02580370 is a Phase 3 study that has completed, run by Revance Therapeutics. The registered enrollment target is 450 participants.
The verdict
NCT02580370, a Phase 3 study, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
Study Summary
This is a safety and efficacy study of botulinum toxin type A in subjects with lateral canthal lines.
Interventions
- BIOLOGICAL Botulinum toxin type A
- BIOLOGICAL Placebo comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02580370
The ClinicalTrials.gov registry entry for NCT02580370 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Botulinum toxin type A is the first listed.
NCT02580370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02580370 about?
NCT02580370 is a clinical study titled "Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines". This is a safety and efficacy study of botulinum toxin type A in subjects with lateral canthal lines.
What is the current status of trial NCT02580370?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2015-09. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02580370?
The interventions under investigation include: Botulinum toxin type A (BIOLOGICAL), Placebo comparator (BIOLOGICAL).
Who is sponsoring clinical trial NCT02580370?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.